Ebian Huda F, Abdelnabi Al-Shabrawy M, Abdelazem Abdallah S, Khamis Tarek, Fawzy Hebatallah M, Hussein Samia
Clinical Pathology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt.
Internal Medicine Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt.
Leuk Res Rep. 2022 May 9;17:100321. doi: 10.1016/j.lrr.2022.100321. eCollection 2022.
CD26 is expressed in all chronic myeloid leukemia (CML) patients. This study investigated the role of CD26 LSCs in diagnosis and follow up of CML patients.
Flow cytometry was performed to evaluate CD26 LSC in peripheral blood (PB) in CML patients. transcript level measurement was performed using standard qRT-PCR technique.
CD26 LSCs were significantly correlated with transcript level at diagnosis and after three months of treatment. CD26+ LSCs also were significantly associated with the risk score after 12 months of treatment.
CD26+ LSCs can be a useful marker in diagnosis and follow up of patients with CML.
CD26在所有慢性髓性白血病（CML）患者中均有表达。本研究调查了CD26白血病干细胞（LSCs）在CML患者诊断及随访中的作用。
采用流式细胞术评估CML患者外周血（PB）中的CD26 LSCs。使用标准定量逆转录聚合酶链反应（qRT-PCR）技术进行转录水平测量。
在诊断时及治疗三个月后，CD26 LSCs与转录水平显著相关。治疗12个月后，CD26 + LSCs也与风险评分显著相关。
CD26 + LSCs可作为CML患者诊断及随访的有用标志物。
